Researchers from the bPRIDE (blood PRotein ldentification to Discriminate dEmentias) and MIRIADE (Multi‐omics Interdisciplinary Research Integration to Address DEmentia diagnosis) projects have co-authored a new paper, published in The Lancet Neurology, entitled " Blood-based biomarkers for Alzheimer's disease: towards clinical implementation".
They also held a joint parallel session at the recent virtual Alzheimer Europe Conference, to share their findings. Here is a summary of the paper: For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but recent results have shown that they could become a reality. Convincing data, generated with new high-sensitivity assays, have emerged with remarkable consistency across different cohorts, but also independent of the precise analytical method used. Concentrations in blood of amyloid and phosphorylated tau proteins associate with the corresponding concentrations in CSF and with amyloid-PET or tau-PET scans. Moreover, other blood-based biomarkers of neurodegeneration, such as neurofilament light chain and glial fibrillary acidic protein, appear to provide information on disease progression and potential for monitoring treatment effects.
Now the question emerges of when and how to bring these biomarkers to clinical practice. This step would pave the way for blood-based biomarkers to support the diagnosis of and development of treatments for Alzheimer's disease and other dementias. You can read the paper, here:
